Pharmaceutical Commerce - February 2026

View the Pharmaceutical Commerce February 2026 issue in an interactive format.

From a deep dive into pharma 3PL strategy to fresh perspectives on PBM economics and rising quality pressures, the February issue sets the tone for a year of industry insight.

The feedback and knowledge of an editorial advisory board are critical to furthering the Pharmaceutical Commerce brand and enhancing industry-wide collaboration.

Sector leaders explore how third-party logistics providers are adapting to advanced therapies, tighter regulations, digital transformation, and expanding cold chain demands.

Rising recalls, tighter FDA enforcement, global supply chain dependencies, and rapid technology shifts are reshaping pharmaceutical quality and compliance—forcing manufacturers to rethink oversight, resilience, and continuous improvement across operations.

Community pharmacies are being squeezed out of local markets, creating pharmacy deserts that raise costs, reduce access, and strain the healthcare system.

These hubs can streamline access, reduce friction across reimbursement and logistics, and improve outcomes, as the CGT pipeline expands and patient demand accelerates.

What 2025 means for the life sciences sector in the New Year.

The commercial PBM model is confronting structural strain as market forces—not regulation—begin to expose the fragility of high-rebate pricing economics.

A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026.

Policy shifts bring meaningful improvements for some—but looming coverage losses and rising premiums threaten to erase those gains.

CMS’s Globe and Guard models extend MFN pricing into Medicare Part B and Part D, signaling a sweeping shift in US drug pricing policy.

At Trade & Channel Strategies, industry executives explored evolving channel models, serialization challenges, generics and biosimilars, and the strategies shaping pharma's future.

Artificial intelligence is fundamentally transforming medical affairs from a reactive function into a strategic partner.